Disseminated_malignant_melanoma_and_recombinant_interferon:_analysis_of_seven_consecutive_phase_II_investigations._We_have_performed_seven_phase_II_trials_with_recombinant_interferons_(IFN)_involving_191_patients_with_biopsy-proved,_measurable_disseminated_malignant_melanoma._The_regimens_and_numbers_of_patients_have_included_IFN-alpha_2A,_50_X_10(6)_U/m2_subcutaneous_(SQ)_TIW_(regimen_A,_31_patients);_IFN-alpha_2A,_12_X_10(6)_U/m2_SQ_TIW_(regimen_B,_30_patients);_IFN-alpha_2A_with_cimetidine_as_an_immunorestorative_agent_(regimen_C,_35_patients);_IFN-gamma_(regimen_E,_29_patients);_IFN-alpha_2A_with_IFN_gamma_(Regimen_E,_20_patients);_IFN-alpha_2A_with_bis-chloroethylnitrosourea_(BCNU)_(regimen_F,_30_patients);_and_IFN-alpha_2A_with_the_biochemical_modulator,_difluoromethylornithine_(DFMO)_(regimen_G,_16_patients)._The_objective_regression_rates_were_as_follows:_A,_23%;_B,_20%;_C,_23%;_D,_10%;_E,_5%;_F,_7%;_G,_0%._Despite_the_higher_response_rate_from_regimen_A,_there_appeared_to_be_no_survival_advantage_from_any_of_these_programs._The_median_time_to_progression_was_1_month_with_a_median_survival_time_of_6_months._Most_regressions_involved_soft_tissue_disease,_were_partial,_and_occurred_within_2-3_months_of_treatment._Four_patients_received_IFN_for_approximately_6_months_and_have_manifested_extraordinarily_durable_regressions_of_greater_than_4+_years._The_alpha-regimens_produced_a_flu-type_illness_and_anorexia_which_were_dose-related._Leukopenia_was_most_noteworthy_with_regimens_containing_gamma-interferon._Ongoing_trials_involving_alternative_and_improved_immune-related_modalities_are_awaited_with_keen_interest.